Back to News
Market Impact: 0.25
Entrada Therapeutics Advances Duchenne Study To Highest Planned Dose Level
Source: Nasdaq
Healthcare & Biotech
A favorable safety review cleared Entrada Therapeutics to test its Duchenne muscular dystrophy candidate at the highest planned dose in an ongoing early-stage clinical study. The update supports continued dose escalation, but the article provides no efficacy results or other clinical data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
TRDA0.65
More News
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Top biotechnology stock pick from Guggenheim
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation
- Needham raises Starling Oncology stock price target on growth outlook
- Why is Olympus stock plunging today?